Alaunos Therapeutics, Inc. - TCRT Net earnings per share for the last 12 months

Alaunos Therapeutics (TCRT) - corporate logo

Alaunos Therapeutics (TCRT) is developing cutting-edge TCR-T therapies to combat solid tumors, leveraging partnerships with medical centers to drive FCF growth. High costs associated with sterile synthesis and patents create a steep barrier to entry, while the environmental footprint remains minimal. The current TTM EPS annual growth rate illustrates financial stability, where 21.40 serves as the baseline parameter value.

alaunos.com (TCRT): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

Financial and market metric breakdowns for Alaunos Therapeutics, Inc. (TCRT)

Fundamental company valuation:TCRT Alaunos Therapeutics Inc.
Flagship merchandise of alaunos.com

This indicator measures the annual growth of net income per share, allowing for an assessment of capital scaling rates. For Alaunos Therapeutics (TCRT), the EPS YoY TTM growth efficiency metric reflects financial stability during the development of TCR-T drugs. The upward trend here confirms the successful commercialization of the Sleeping Beauty platform. Sharp spikes in values often create noise that masks long-term trends. While steady growth reduces investment risks, excessive acceleration may signal imminent market saturation.